Biochemical Engineering Special Interest Group
biological engineering professionals
27 May 2016

Celltrion to expand capacity by 170,000L

Celltrion will invest $275m at its biosimilar production site in Korea to ramp up capacity from 140,000L to 310,000L by 2021. Plant 1, consisting of four 12,500L production lines is set to double by 2018 with commercial production expected to start in 2019. Additionally, a third plant, initially expected to add 90,000L of capacity, will increase to 120,000L with commercial operation starting in 2021. Source: BiopharmaReporter 27/5/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).